Onivyde for the therapy of multiple solid tumors.

Abstract

Drug delivery system based on nanobiotechnology can improve the pharmacokinetics and therapeutic index of chemotherapeutic agents, which has revolutionized tumor therapy. Onivyde, also known as MM-398 or PEP02, is a nanoliposomal formulation of irinotecan which has demonstrated encouraging anticancer activity across a broad range of malignancies, including pancreatic cancer, esophago-gastric cancer, and colorectal cancer. This up-to-date review not only focuses on the structure, pharmacokinetics, and pharmacogenetics of Onivyde but also summarizes clinical trials and recommends Onivyde for patients with advanced solid tumors.

• Authors: Haijun Zhang
• Journal: OncoTargets and therapy (Onco Targets Ther) Vol. 9 Pg. 3001-7 ( 2016) ISSN: 1178-6930 [Print] New Zealand
• PMID: 27284250 (Publication Type: Journal Article, Review)